Testagen

1. Overview

Testagen is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Gly (KEDG) and a molecular weight of 447.44 g/mol (C17H29N5O9; CAS 1026993-38-3). It was developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology as the synthetic active component originally identified from testicular tissue extracts [4] [5].

Testagen belongs to Khavinson's class of "cytogen" synthetic peptide bioregulators -- short-chain peptides (2-4 amino acids) proposed to restore organ function through direct interaction with gene regulatory elements rather than through conventional cell-surface receptor signaling [2] [5]. It is specifically designated as a testicular bioregulator, proposed to support testosterone biosynthesis and male reproductive function by modulating gene expression in Leydig cells and related endocrine tissues [1] [6].

Unlike the six peptide pharmaceuticals registered in Russia from Khavinson's program (Thymalin, Thymogen, Cortexin, Retinalamin, Prostatilen, and Epithalamin), Testagen has not achieved pharmaceutical registration. It is marketed in Russia and internationally as a peptide dietary supplement in the "cytogen" (synthetic) and "cytomax" (natural extract) product categories [5] [6]. No clinical trials are registered on ClinicalTrials.gov, and no Western regulatory agency has evaluated Testagen for any therapeutic indication.

The evidence base for Testagen is notably thin compared to more established Khavinson peptides. One published clinical study examined its effects in men with chronic prostatitis and androgenic deficiency [1], and animal studies have explored effects on thyroid function. The broader theoretical framework of peptide-DNA interaction has been described in systematic reviews [2], but specific mechanistic validation for KEDG in testicular tissue remains limited.

Sequence

Lys-Glu-Asp-Gly (KEDG)

Molecular Weight

447.44 g/mol

Chemical Formula

C17H29N5O9

CAS Number

1026993-38-3

Mechanism

Proposed epigenetic regulation of steroidogenic gene expression via peptide-DNA interaction in testicular and thyroid tissue

Routes Studied

Oral (capsule), subcutaneous

Regulatory Status

Not approved as a pharmaceutical; marketed in Russia as a peptide dietary supplement (cytomax/cytogen class)

2. Mechanism of Action

Proposed Epigenetic Regulation of Steroidogenesis

According to Khavinson's peptide bioregulation theory, Testagen (KEDG) crosses both cell and nuclear membranes to interact directly with DNA in target tissues [2] [3]. The tetrapeptide is proposed to recognize specific DNA sequences and methylation patterns within promoter regions of genes involved in steroidogenesis, thereby modulating transcription of enzymes in the testosterone biosynthetic pathway [2].

This mechanism was demonstrated generally for short peptides in HeLa cells, where fluorescence-labeled peptides of similar length penetrated cell nuclei and showed specific interactions with deoxyribooligonucleotides and double-stranded DNA [3]. However, these experiments were performed with the general class of short peptides, and specific binding data for KEDG in testicular cell chromatin has not been published.

Leydig Cell Stimulation

Testagen is proposed to promote testosterone biosynthesis by stimulating Leydig cell activity and improving testicular cellular metabolism [1]. Leydig cells in the interstitial compartment of the testes are the primary source of testosterone in males, and their function declines with age. The proposed mechanism involves KEDG-mediated upregulation of genes encoding steroidogenic enzymes (StAR, CYP11A1, CYP17A1, 3-beta-HSD, 17-beta-HSD) that catalyze the conversion of cholesterol to testosterone [1] [7].

HPG Axis Modulation

Through its regulatory activity in testicular tissue, Testagen is proposed to help restore normal communication within the hypothalamic-pituitary-gonadal (HPG) axis. This includes normalization of feedback signaling between testicular testosterone production, pituitary LH/FSH secretion, and hypothalamic GnRH release [1] [6].

Thyroid Effects

Animal studies have reported that KEDG prevents atrophic changes in the thyroid gland and alleviates secondary hypothyrosis in hypophysectomized birds, increasing levels of thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4) [6]. This cross-tissue activity is somewhat unexpected for a peptide designated as testicular-specific and may reflect the presence of shared DNA regulatory elements in multiple endocrine tissues.

Theoretical Limitations

The core mechanism proposed for Testagen -- direct peptide-DNA binding as a means of gene regulation -- remains unvalidated by independent laboratories. The concept that a tetrapeptide can function as a tissue-specific transcription regulator through direct DNA interaction is outside the mainstream of Western molecular biology [7] [2]. No crystal structures, binding affinity measurements, or genome-wide binding studies specific to KEDG have been published.

3. Researched Applications

Androgenic Deficiency with Chronic Prostatitis

The only published clinical study of Testagen examined its effects in men with chronic abacterial prostatitis accompanied by androgenic deficiency [1]. Treatment with Testagen resulted in:

• Enhancement of uroflowmetry indicators (improved urinary flow)
• Reduction in prostatic inflammation markers
• Noticeable elevation in total serum testosterone levels

This study was published in a Ukrainian endocrinology journal and has not been replicated by independent research groups.

Thyroid Support

Animal studies in hypophysectomized quail demonstrated that KEDG prevented thyroid atrophy and restored thyroid hormone levels (TSH, T3, T4), with effects more pronounced in younger animals [6]. This suggests potential applications in thyroid function support, though no human clinical studies of KEDG for thyroid conditions have been published.

Male Reproductive Health

Based on its proposed mechanism of Leydig cell stimulation and HPG axis modulation, Testagen has been positioned in the supplement market for age-related testosterone decline, spermatogenesis support, and overall male reproductive function [1] [5]. However, controlled clinical trials demonstrating efficacy for these indications are absent.

Broader Bioregulator Framework

Testagen is used within Russian clinical practice as part of combined peptide bioregulator protocols, often in conjunction with other organ-specific preparations such as Prostatilen (prostate), Vilon (thymus), and Epithalon (pineal gland) [6] [14]. The rationale for combination therapy is that age-related decline affects multiple organ systems simultaneously, requiring multi-targeted peptide intervention.

4. Clinical Evidence

The clinical evidence for Testagen is minimal:

Clinical Studies: One published study in men with chronic prostatitis and androgenic deficiency reported improvements in urinary flow, prostatic inflammation, and serum testosterone [1]. The study was not randomized, double-blind, or placebo-controlled, and sample size details are not readily accessible in English-language literature.

Animal Studies: Thyroid function studies in hypophysectomized birds demonstrated restoration of thyroid hormone levels following KEDG administration [6].

In Vitro Studies: General short peptide nuclear penetration studies support the theoretical mechanism but do not provide specific evidence for KEDG in testicular tissue [3].

Systematic Reviews: The peptide-DNA interaction mechanism has been reviewed systematically, providing the theoretical framework within which Testagen's activity is proposed [2].

Testagen has the weakest evidence base among the established Khavinson peptide bioregulators. No randomized controlled trials, dose-response studies, or pharmacokinetic analyses have been published.

5. Dosing in Published Research

The following doses have been reported in published research and supplement protocols. These are not recommendations and should not be interpreted as therapeutic guidance.

In the Russian supplement market, Testagen is available in capsule form, typically containing 0.2 mg of KEDG peptide with additional excipients. Standard supplement protocols suggest 1-2 capsules daily for 10-30 days, with courses repeated 2-3 times per year [5] [6]. No formal dose-finding studies or dose-response characterization has been published.

6. Safety and Side Effects

No adverse events have been reported in the limited published literature on Testagen [1]. In the broader context of Khavinson's short peptide bioregulators, preparations in this class have been described as well-tolerated with minimal side effects across decades of use in Russian clinical practice [6] [14].

However, critical safety data are entirely absent:

• No systematic toxicology studies have been published.
• No reproductive toxicity studies exist, despite the peptide's intended use for reproductive function.
• No drug interaction studies have been conducted.
• No pharmacokinetic data (oral bioavailability, half-life, metabolism) are available.
• Long-term safety of exogenous modulation of steroidogenic gene expression has not been evaluated.
• Theoretical concerns exist regarding effects on hormone-sensitive cancers (prostate, testicular) if testosterone modulation is confirmed.

7. Relationship to Other Khavinson Tetrapeptides

Testagen (KEDG: Lys-Glu-Asp-Gly) shares significant sequence similarity with other Khavinson tetrapeptides:

• Epithalon (AEDG: Ala-Glu-Asp-Gly) -- the pineal bioregulator differs only in the first amino acid position (Ala vs. Lys). This raises questions about the claimed tissue-specificity of these peptides, as a single amino acid substitution is proposed to completely redirect organ targeting from pineal gland to testes.
• Livagen (KEDA: Lys-Glu-Asp-Ala) -- the hepatic bioregulator shares the first three amino acids (KED) with Testagen, differing only in the terminal residue (Ala vs. Gly).
• Vesugen (KED: Lys-Glu-Asp) -- the vascular bioregulator is essentially the first three residues of Testagen.

This pattern of closely related sequences with different claimed tissue specificities is a distinctive feature of Khavinson's peptide bioregulator program and has been both defended by proponents as evidence of sequence-dependent epigenetic targeting and questioned by skeptics as lacking mechanistic validation [2] [12].

8. Limitations and Transparency

Testagen has the thinnest evidence base among the Khavinson peptide bioregulators covered in this encyclopedia:

• Only one clinical study has been published, in a Ukrainian endocrinology journal, without English-language full text readily available.
• No randomized controlled trials, dose-response studies, or formal pharmacokinetic analyses exist.
• The peptide's close sequence similarity to Epithalon and Livagen raises questions about claimed tissue-specific targeting mechanisms.
• No independent replication of any Testagen-related finding has been published.
• The product is marketed as a dietary supplement rather than a registered pharmaceutical, even in Russia.
• The proposed mechanism (direct peptide-DNA interaction for tissue-specific gene regulation) has not been validated for KEDG specifically.

9. Pharmacokinetics

No pharmacokinetic studies have been published for Testagen (KEDG). As a tetrapeptide of 447.44 g/mol, it faces the same fundamental pharmacokinetic challenges as other Khavinson bioregulators: rapid proteolytic degradation, uncertain oral bioavailability, and unknown tissue distribution.

The glycine residue at the C-terminus is one of the smallest amino acids and is readily cleaved by carboxypeptidases, offering no protease resistance. The lysine at the N-terminus is similarly susceptible to aminopeptidases. No plasma half-life, oral bioavailability, or tissue concentration data have been published for KEDG.

The proposed target tissue (Leydig cells in the testicular interstitium) is accessible via systemic circulation through the testicular vasculature. However, the blood-testis barrier, formed by Sertoli cell tight junctions, protects the seminiferous tubule compartment. While Leydig cells lie outside this barrier (in the interstitial space), reaching them still requires intact peptide to survive systemic proteolysis and transit through testicular capillary endothelium.

The clinical study used an oral capsule formulation [1], but no data confirm that intact KEDG reaches testicular tissue at biologically active concentrations following oral dosing. The testosterone elevation observed clinically [1] could potentially reflect indirect effects (e.g., gut-peptide signaling, immune modulation, or effects of degradation products) rather than direct Leydig cell targeting.

A 2025 study investigating KEDG's adsorption properties on copper surfaces [15] provided physicochemical data relevant to peptide behavior but not to in vivo pharmacokinetics.

10. Dose-Response

No dose-response studies have been published for Testagen. The clinical study in chronic prostatitis used a single protocol without dose comparison [1]. The supplement protocol (1-2 capsules of 0.2 mg daily) represents a 2-fold dose range without optimization data.

The absence of dose-response information is particularly problematic for an endocrine-active peptide claimed to modulate testosterone biosynthesis. For conventional testosterone-modulating agents (clomiphene, enclomiphene, hCG), dose-response relationships with serum testosterone levels are well characterized. For Testagen, no such relationship has been published.

The animal study in hypophysectomized birds observed thyroid hormone effects that were "more pronounced in younger animals," suggesting an age-dependent dose-response relationship. However, the specific doses used and the quantitative relationship between dose and thyroid hormone levels were not detailed in accessible abstracts.

Whether there is a ceiling dose above which no additional testosterone benefit occurs, or a threshold dose below which no effect is observed, is entirely unknown.

11. Comparative Effectiveness

Testagen (KEDG) vs. Epithalon (AEDG)

These tetrapeptides differ only in the first amino acid (Lys vs. Ala), yet claim completely different tissue specificities (testes vs. pineal gland). This is the closest sequence similarity among any pair of Khavinson peptides with different claimed targets, making it a critical test case for the tissue-specificity hypothesis. No head-to-head comparison of KEDG and AEDG in testicular or pineal tissue has been published. The shared EDG C-terminal sequence raises the possibility that both peptides may have overlapping effects that have not been characterized.

Testagen vs. Clomiphene Citrate

Clomiphene is a selective estrogen receptor modulator (SERM) used off-label for male hypogonadism and infertility. It acts through HPG axis modulation (blocking hypothalamic estrogen negative feedback) and has multiple RCTs demonstrating testosterone elevation. Clomiphene has defined pharmacokinetics (oral bioavailability approximately 100%, half-life approximately 5-7 days) and dose-response data. Testagen has one uncontrolled clinical study and no pharmacokinetic data. The evidence gap is vast.

Testagen vs. hCG (Human Chorionic Gonadotropin)

hCG directly stimulates Leydig cells via LH receptor activation and is the standard of care for Leydig cell stimulation. It has extensive clinical evidence for hypogonadism and male infertility. Testagen proposes indirect Leydig cell stimulation through epigenetic gene regulation. No comparative data exist.

Testagen vs. Other Khavinson Peptides

Testagen has the weakest evidence base among the established Khavinson peptide bioregulators. It lacks the primate data of Pancragen, the mortality studies of Epithalon/epithalamin, the pharmaceutical approval of Cortexin or Thymalin, and the chromatin remodeling data of Livagen or Prostamax. It is one of the least validated peptides in the entire Khavinson bioregulator system.

12. Enhanced Safety

No adverse events have been reported in the limited Testagen literature [1]. The broader Khavinson safety profile reports no toxic, allergic, or adverse effects across the entire bioregulator product line [6][14].

As a tetrapeptide of common L-amino acids, KEDG is expected to be rapidly degraded to its constituent amino acids, which are all abundant in normal metabolism. This rapid degradation provides an inherent safety margin against systemic accumulation.

However, several specific safety concerns warrant consideration for an endocrine-active peptide targeting testosterone biosynthesis:

Hormone-sensitive cancer risk: Testosterone stimulates growth of prostate cancer cells. Any agent that elevates testosterone levels should be evaluated for effects in men with occult or diagnosed prostate cancer. No PSA monitoring data or prostate cancer risk assessment has been published for Testagen.

HPG axis disruption: Exogenous modulation of testosterone biosynthesis could theoretically disrupt hypothalamic-pituitary-gonadal feedback, potentially causing paradoxical suppression of endogenous production after discontinuation. This concern is well-established for exogenous testosterone and hCG but has not been evaluated for Testagen.

Reproductive effects: Despite targeting reproductive tissue, no reproductive toxicity or fertility impact studies have been conducted. Effects on spermatogenesis, sperm quality, or female partner outcomes are entirely unknown.

Thyroid cross-reactivity: The animal study showing thyroid effects (TSH, T3, T4 elevation) in hypophysectomized birds raises questions about unintended endocrine effects beyond the gonads. No monitoring for thyroid function changes has been reported in human studies.

No drug interaction studies exist. Potential interactions with exogenous testosterone, 5-alpha-reductase inhibitors, aromatase inhibitors, SERMs, or other hormonal agents are unknown.

13. Related Peptides

See also: Epithalon, Vesugen, Vilon

14. References

1. [1] Rossikhin VV, Hoshchenko YuO, Osipov PG (2011). Efficacy of testosterone synthesis inductor application Testagen in androgenic deficiency in patients with chronic abacterial prostatitis. Problems of Endocrine Pathology.
2. [2] Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
3. [3] Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
4. [4] Khavinson VK (2002). Peptides and ageing. Neuro Endocrinol Lett. PubMed
5. [5] Khavinson VK (2020). Peptide medicines: past, present, future. Klin Med (Mosk). PubMed
6. [6] Khavinson VK, Kuznik BI, Ryzhak GA (2013). Peptide bioregulators: a new class of geroprotectors. Report 2. Clinical studies results. Adv Gerontol. PubMed
7. [7] Anisimov VN, Khavinson VK (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
8. [8] Morozov VG, Khavinson VK (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. DOI PubMed
9. [9] Khavinson VK, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. DOI PubMed
10. [10] Khavinson VK, Linkova NS, Kvetnoy IM (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed
11. [11] Kuznik BI, Linkova NS, Khavinson VK (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. Int J Mol Sci. DOI PubMed
12. [12] Ilina A, Khavinson V, Linkova N, Petukhov M (2025). Overview of Epitalon -- Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. DOI PubMed
13. [13] Khavinson VK, Linkova NS, Dyatlova AS, Kuznik BI, Umnov RS (2021). The use of Thymalin for immunocorrection and molecular aspects of biological activity. Biol Bull Rev. DOI PubMed
14. [14] Khavinson VK, Morozov VG (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. PubMed
15. [15] Kasyanenko NA, Khavinson VK, Linkova NS (2025). Testagen peptide inhibitory effect and adsorption properties on copper surfaces in saline environments. Molecules. DOI